OR WAIT 15 SECS
Sartorius Stedim Biotech has launched a new automated parallel bioreactor system for perfusion culture.
Sartorius Stedim Biotech (SSB), a supplier for the biopharmaceutical industry, has launched a new automated parallel bioreactor system-the ambr 250 high throughput (ht) perfusion system. Developed in collaboration with major biopharma companies, the ambr 250ht perfusion system has been designed for rapid cell culture perfusion process development to optimize production of therapeutic antibodies. It combines 12 or 24 single-use perfusion mini bioreactors (100–250 mL working volume) with associated single-use perfusion components, all controlled by one automated workstation. The combination of this multi-parallel processing capacity and fully single-use perfusion vessel enables scientists to perform more perfusion culture experiments in less time and with less cost compared with traditional perfusion-enabled bench top bioreactors. This new innovation supports a range of hollow fiber perfusion applications, enabling design-of-experiments (DoE) studies for high cell density process development in a quality-by-design (QbD) approach.
The novel perfusion bioreactor assembly is based on the ambr 250 bioreactor design. New components such as high-efficiency spargers, perfusion pump chambers, and an industry-standard hollow fibre for cell retention filter enable intensified cell culture processing. The geometrical similarity of the mini perfusion bioreactor design to BIOSTAT STR pilot and manufacturing scale bioreactors enables rapid scale-up of optimized perfusion processes and shorter development timelines.
The ambr 250ht perfusion system is simple to set up and use because of the fully assembled and irradiated perfusion bioreactors, which include all the essential components. For example, single-use sensors continuously monitor pressure at the culture fluid inlet and permeate outlet, thereby, enabling online monitoring of transmembrane pressure, as well as standard parameters such as pH and dissolved oxygen.
Source: Sartorius Stedim Biotech